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endogenous amino acids or proteins might not be able to go through the protein translational machinery for genetic incorporation. For these reasons, Uaas that have been incorporated into proteins through orthogonal tRNA-synthetase pairs hitherto have contained either chemically inert or bioorthogonal side chains 5 . We hypothesized that this challenge could be overcome by proximity-enhanced bioreactivity (Fig. 1a) . Specifically, the Uaa should not react with any free natural amino acids under physiological conditions; but after the Uaa is incorporated and placed in proximity to its target natural amino acid residue into proteins, the increased effective concentration and appropriate orientation of their side chains should then facilitate the reaction. Reactivity between small molecules is enhanced when they are brought close by DNA templates 6 . In addition, proximity effects for enhancing reactivity between proteins and small molecules have been found in natural products 7 and exploited in the development of irreversible ligand binding 8 , small-molecule inhibitors and activity-based protein profiling 9 . Because proximity of amino acid side chains can be readily attainable either within proteins or at the interface of interacting proteins, we reasoned that it would be feasible to harness the proximity of a designed Uaa and a target natural amino acid for selective formation of a new covalent bond.
We designed p-2′-fluoroacetylphenylalanine 1 (F fact , Fig. 1b) as the Uaa to react with cysteine. The sulfhydryl group of cysteine has the highest nucleophilicity among chemical groups occurring in natural amino acid side chains, so we expected that a weak electrophilic group, when close to a cysteine residue, would selectively react with it. The C-F bond is strong, and F is not a very good leaving group in S N 2 reactions, but the carbonyl group of F fact increases its reactivity, making the C a weak electrophile. In fact, small-molecule or peptidyl fluoromethyl ketones have been shown to react irreversibly with cysteine in the active site of a cysteine proteinase 10 and the S6 kinase 11 .
F fact was synthesized via a four-step approach (Fig. 1c,  Supplementary Note, Supplementary Fig. 1 ). To test the reactivity of F fact toward cysteine, we incubated them at different concentrations and analyzed the reaction using HPLC-mass spectrometry (HPLC-MS). In reactions containing 1 mM F fact and 50 µM cysteine, no F fact reacted with cysteine (data not shown). A small percentage (<5%) of F fact reacted with cysteine when cysteine concentration was increased to 1 mM. In contrast, in reactions containing 1 mM F fact and 10 mM cysteine, F fact was completely converted to the product (Fig. 1d) . The intracellular concentration of free cysteine is ~19 µM in Escherichia coli 12 , and proximity increases the effective concentration of reactants. Therefore, these concentration-dependent results suggest that adding an unnatural covalent bond to proteins through proximityenhanced bioreactivity Covalent peptide bonds in the backbone and noncovalent interactions among amino acid side chains provide the essential framework for protein structure and function. Covalent disulfide bonds formed between two cysteine residues contribute another fundamental type of linkage, providing more stability and selectivity than noncovalent interactions. Indeed, the disulfide bond is crucial for the folding, stability and activity of a variety of proteins such as antibodies, cytokines and membrane-associated receptors 1,2 . However, its reversibility and redox sensitivity impose limitations on protein expression, engineering and applications in biotechnology and therapeutics 3 . Isopeptide bonds between lysine and asparagine or aspartate have also been discovered, but they form only in the hydrophobic protein interior and require an essential glutamate or aspartate residue to catalyze the reaction 4 . Additional types of covalent linkages formed autocatalytically would expand avenues for generating novel protein properties and functions. Here we report the design and application of a new covalent bond that is formed based on proximity-enhanced reactivity between an unnatural amino acid (Uaa) and a nearby cysteine residue.
To generate a new covalent bond between a Uaa and a natural amino acid, the side chain of the Uaa must be reactive toward that of the target natural amino acid. However, because the natural amino acid is ubiquitously present in proteins and inside cells, uncontrolled reactivity will result in nonspecific linkages, causing cytotoxicity. In addition, a Uaa that is bioreactive toward F fact would not react with free cysteine inside E. coli cells, but its reactivity with cysteine could be enhanced by proximity.
To determine if a covalent bond could be formed at the interface of two interacting proteins, we genetically incorporated F fact into the Z SPA affibody 13 and tested whether the resultant affibody could covalently capture its substrate Z protein modified with a cysteine residue. We chose to incorporate F fact at Asp36 in the affibody and to mutate Asn6 to cysteine in the Z protein (Fig. 2a) because these two sites are in close proximity at the interface and have been used previously for cross-linking through chemical modification 14 . Because F fact is structurally similar to p-acetyl-lphenylalanine (F act , Fig. 2b ), differing only in having a hydrogen atom replaced by fluorine, we reasoned that the orthogonal tRNAsynthetase pair evolved for incorporating F act (ref. 15) should be able to incorporate F fact into proteins. We mutated Asp36 into an amber codon TAG in the affibody gene to encode Uaa and coexpressed the mutant gene with the orthogonal tRNA-synthetase genes in E. coli. Gel separation of the purified affibody showed that production of the full-length affibody was markedly increased (43-fold) when F fact was included in the growth medium (Fig. 2c) . We then analyzed the purified mutant affibody by electrospray ionization MS (ESI-MS) (Fig. 2d) , which indicated that F fact was We next tested the intermolecular reaction of the mutant affibody (D36F fact ) with the mutant Z protein (N6C). We incubated the two proteins at a 4:1 ratio in Tris buffer (pH 8.0) or PBS (pH 7.4) at 37 °C for 1 h and analyzed the reaction mixture by SDS-PAGE under denaturing conditions. We detected a band with molecular weight corresponding to the affibody-Z protein complex (Fig. 2e) , indicating that the two were covalently linked. The yield of covalent complex formation was 63 ± 3% (n = 3). ESI-MS analysis of the reaction product confirmed that the complex was covalently linked by F fact reacting with cysteine (Fig. 2f) . This complex band did not form when F fact 36 was replaced by the non-fluorinated F act in the affibody or when Cys6 was replaced by asparagine in the Z protein (Fig. 2e) . In addition, when we placed cysteine at Z protein Asn3 instead of Asn6, no covalent affibody-Z complex was formed (Fig. 2e) . Taken together, these results indicate that the covalent bond formed by F fact and cysteine was dependent on the presence of both amino acids in close proximity.
We further demonstrated the compatibility of this intermolecular bond formation in mammalian cells. We incorporated F fact into the corticotropin release factor receptor type 1 (CRF-R1) 16 , a class B G protein-coupled receptor (GPCR), at a site near the tip of transmembrane helix 6 (Fig. 3a) . Available three-dimensional structures indicate that the corresponding helix of the class A GPCR is involved in ligand interaction. Cysteine was introduced into different positions of urocortin-1 (Ucn-1), a native 40-amino-acid peptide agonist of this receptor. We incubated the cysteineUcn-1 (Cys-Ucn-1) ligand analogs individually with HEK293T cells expressing the F fact -CRF-R1 mutant, and then resolved cell lysates by reducing SDS-PAGE and immunoblotted them with an antibody specific for Ucn-1 (anti-Ucn-1). Only when cysteine was introduced at position 12 of Ucn-1 was a covalent ligandreceptor complex formed (Fig. 3b, Supplementary Fig. 2 ). These results demonstrate that the F fact -cysteine reaction can be used in mammalian cells to site-specifically capture peptide-protein interactions under native conditions.
To explore whether the covalent bond between F fact and cysteine could be formed intramolecularly within a protein, we introduced these amino acids into fluorescent proteins to covalently link the fluorophore to the β-barrel. We replaced Tyr67 of the fluorophore with F fact and the proximal Ser146 in the β-barrel with cysteine in the red fluorescent protein mPlum 17 (Supplementary Results, Supplementary Methods and Supplementary Fig. 3) . ESI-MS analysis of the expressed S146C-Y67F fact mutant indicated that the F fact 67-Cys146 bond was formed (Supplementary Fig. 3c) . In comparison to the isosteric mutant S146C-Y67F act lacking the fluorine atom and thus the covalent bond, the S146C-Y67F fact mutant showed a 4.6-fold greater quantum yield and a 0.86-fold greater photon output (Supplementary Fig. 3e,g ). Covalent bond formation and similar effects on fluorescence properties were also observed when the F fact -cysteine pair was introduced into another red fluorescent protein, mKate2 (ref. 18) (Supplementary Results and Supplementary Fig. 4 ).
In conclusion, we have shown that it is possible to add a new covalent linkage to proteins by designing proximity-enhanced bioreactivity between side chains of a Uaa and a natural proteinogenic amino acid. We expect that this approach can be used to generate other new covalent bonds for proteins by targeting other natural amino acids. The ability to introduce new covalent linkages into proteins will afford new avenues toward protein properties and functions that were previously inaccessible because of the limitations of disulfide bonding, which will find broad applications in biological studies, protein therapeutics and synthetic biology. Plasmid construction. All plasmids were assembled by standard cloning methods and confirmed by DNA sequencing. The Z protein and mutants were expressed using the pBAD-Z plasmids, in which target genes were cloned into pBAD (Invitrogen) using the Spel and HindIII sites. A His 6 tag was appended to the C terminus for purification. The affibody and mutants were expressed using pLei-tRNA opt -Aff and pBK-LW1RS 15 . pLeitRNA opt -Aff was constructed from pLei-tRNA opt -STAT3 (ref. 21) by replacing the STAT3 gene with the affibody gene using the SpeI and BlpI sites. A His 6 tag was appended at the C terminus of the affibody for purification. Primer sequences can be found in Supplementary Table 1 . mPlum and mutants were expressed with pBAD-mPlum 22 and pLei-tRNA opt -factRS. pLei-tRNA optfactRS was constructed from pLei-tRNA opt -STAT3 by replacing the STAT3 gene with the LW1RS gene using the SpeI and BglII sites, and no His 6 tag was appended at the C terminus of the factRS. mKate2 and mutants were expressed with pLei-tRNA optmKate2 and pBK-LW1RS. pLei-tRNA opt -mKate2 was constructed from pLei-tRNA opt -STAT3 by replacing the STAT3 gene with the mKate2 gene using the SpeI and BglII sites. The TAG codon for encoding the Uaa was introduced with the QuikChange sitedirected mutagenesis method (Stratagene). For the affibody and Z proteins, two amino acids (threonine and serine) were introduced right after the N-terminal methionine by the SpeI site. Numbering of the amino acid residues for affibody and Z followed the original numbering 13 . The rat CRF-R1 gene with a TAG stop codon at L329 position was PCR amplified from pAIO-Azi-CRFR1 (ref. 23 ) and cloned into pcDNA3.1(+) using the EcoRI and NotI restriction sites to afford plasmid 329tag-CRF-R1-Flag. A Flag tag was appended at the C terminus for western blot detection. Plasmid pIre-Keto3 was constructed to express the tRNA CUA Tyr derived from the Bacillus stearothermophilus tRNA Tyr and the F act -specific synthetase EKetoRS, which was derived from the E. coli TyrRS with the following mutations: Y37I, D182G, F183M, L186A and D265R (ref. 24) . The tRNA CUA Tyr without the last CCA trinucleotide was driven by the U6 promoter and flanked by the 3′-flanking sequence derived from a human initiator methionine tRNA gene 25 . The tRNA cassette was repeated 3 times in tandem. The EKetoRS gene was driven by the PGK promoter.
Protein expression and purification. E. coli BL21 cells harboring expression plasmids were grown at 37 °C in glycerol minimal medium supplemented with 1 mM of F act or 2 mM of racemic F fact (effective concentration of l-F fact was 1 mM) when appropriate. Protein expression was induced with 0.5 mM IPTG (for pLei plasmids) or 0.2% arabinose (for pBAD plasmids) when the OD 600 of cells reached 0.5. After 4-6 h, cells were lysed by sonication, and proteins were purified using Ni-NTA resin (Qiagen) by following the published conditions and procedures 26 . Yields for F fact containing proteins were: affibody 3.1 mg/L, mPlum 2.5 mg/L, mKate2 3.5 mg/L. Mass spectrometry. Intact proteins were analyzed by ESI-TOF using an Agilent 6210 mass spectrometer coupled to an Agilent 1100 HPLC system. Two micrograms of protein samples were injected by an auto-sampler and separated on an Agilent Zorbax SB-C8 column (2.1 mm ID × 10 cm length) by a reverse-phase gradient of 0-80% acetonitrile for 15 min. Mass calibration was performed right before the analysis. Protein spectra were averaged and the charge states were deconvoluted using Agilent MassHunter software.
Affibody-Z complex formation. The purified Z SPA affibody (75 µM) and Z protein (19 µM) were incubated with molar ratio of 4:1 in 1× phosphate-buffered saline (PBS) (pH 7.4) or Tris buffer (50 mM Tris, 500 mM NaCl, pH 8.0) at 37 °C for 1 h. SDS loading buffer containing 100 mM of dithiothreitol was added to the reaction mixture, which was then boiled at 100 °C for 8 min to disrupt noncovalent interactions. The boiled samples were then separated by 16.5% Tris-tricine gels and stained with Coomassie blue. Band intensities were quantified by using ImageJ. The cross-linking yield was calculated by (I Z + I affibody -I cross-linked )/2I Z , in which I represents band intensity.
CRF-R1 cross-linking.
The sequence of Ucn-1 is DDPPLSIDL TFHLLRTLLELARTQSQRERAEQNRIIFDSV. HEK293T cells were transfected with 8 µg pIre-Keto3 plasmid and 4 µg 329 tag-CRF-R1-Flag plasmid using Lipofectamine 2000 in a 10-cm dish, and cultured with 0.25 mM F fact for 48 h. These cells were then divided into 6 aliquots, 5 of which were incubated with the 5 different Cys-Ucn-1 ligand analogs (100 nM) individually in HEPES buffer (25 mM HEPES, pH 7.5, 5 mM KCl, 5 mM MgCl 2 , 140 mM NaCl, 0.1% BSA, 0.01% Triton X-100) containing 1 mM TCEP (tris(2-carboxyethyl)phosphine) for 90 min. The last aliquot was incubated with 100 nM [Bpa 12 ]-Ucn in the same condition, after which it was photocross-linked for 20 min in a Spectrolinker XL-1500A (365 nm) at 4,400-5,000 µW/cm 2 . Cell pellets for all samples were separately collected, lysed, denatured with 100 mM DTT for 30 min at 37 °C, and then separated by SDS-PAGE on 10% acrylamide Tris-Gly minigels. Proteins were transferred to a PVDF membrane and immunoblotted with a polyclonal rabbit antiurocortin. For detection of the Flag tag, the monoclonal mouse anti-Flag M2-peroxidase conjugate (cat. no. A8592) purchased from Sigma was used.
